MIRA Pharmaceuticals, Inc. Erez Aminov, CEO

MIRA is developing a newmolecular synthetic THC analog called MIRA1a, designed for the treatment ofadult patients with anxiety and cognitive decline, typically associated withearly-stage dementia.   MIRA’s initial focus willbe a dual path: potentially winning in traditional pain and anxiety markets aswell as the marijuana analog markets with a potentially safe and effective option if approvedby the FDA.